News

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...
Zacks Investment Research on MSN5d
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...
Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to ...
Data on Novo Nordisk Experimental Weight-Loss Drug Show Mostly Mild Side Effects
(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema ...
U.S. News & World Report25d
Novo Nordisk Starts New CagriSema Weightloss Drug Trial
COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential ...